ZA969584B - Sulfonamide inhibitors of matrix metalloproteinases - Google Patents
Sulfonamide inhibitors of matrix metalloproteinasesInfo
- Publication number
- ZA969584B ZA969584B ZA969584A ZA969584A ZA969584B ZA 969584 B ZA969584 B ZA 969584B ZA 969584 A ZA969584 A ZA 969584A ZA 969584 A ZA969584 A ZA 969584A ZA 969584 B ZA969584 B ZA 969584B
- Authority
- ZA
- South Africa
- Prior art keywords
- pct
- date
- matrix metalloproteinases
- gelatinase
- sec
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 231100000397 ulcer Toxicity 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 abstract 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 abstract 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 abstract 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US737295P | 1995-11-17 | 1995-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA969584B true ZA969584B (en) | 1997-06-02 |
Family
ID=21725784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA969584A ZA969584B (en) | 1995-11-17 | 1996-11-14 | Sulfonamide inhibitors of matrix metalloproteinases |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US5977141A (enExample) |
| EP (1) | EP0874836B1 (enExample) |
| JP (1) | JP2000514779A (enExample) |
| AT (1) | ATE225779T1 (enExample) |
| AU (1) | AU727569B2 (enExample) |
| BG (1) | BG63967B1 (enExample) |
| BR (1) | BR9611487A (enExample) |
| CZ (1) | CZ291659B6 (enExample) |
| DE (1) | DE69624262T2 (enExample) |
| DK (1) | DK0874836T3 (enExample) |
| ES (1) | ES2184893T3 (enExample) |
| HU (1) | HUP9902083A3 (enExample) |
| IL (1) | IL123901A (enExample) |
| NO (1) | NO310231B1 (enExample) |
| NZ (1) | NZ321293A (enExample) |
| PL (1) | PL326700A1 (enExample) |
| PT (1) | PT874836E (enExample) |
| SK (1) | SK282833B6 (enExample) |
| WO (1) | WO1997019068A1 (enExample) |
| ZA (1) | ZA969584B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6500948B1 (en) | 1995-12-08 | 2002-12-31 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof |
| PT874830E (pt) * | 1995-12-08 | 2003-06-30 | Agouron Pharma | Inibidor de metaloproteinases composicao farmaceutica contendo este inibidor e a utilizacao farmaceutica e metodo util para a sua preparacao |
| US6747027B1 (en) * | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
| CA2256716A1 (en) * | 1996-09-04 | 1998-03-12 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
| KR20000068415A (ko) | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법 |
| US6624177B1 (en) | 1996-09-04 | 2003-09-23 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
| US6228869B1 (en) | 1996-10-16 | 2001-05-08 | American Cyanamid Company | Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US5929097A (en) * | 1996-10-16 | 1999-07-27 | American Cyanamid Company | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| US5977408A (en) * | 1996-10-16 | 1999-11-02 | American Cyanamid Company | Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| US6174915B1 (en) | 1997-03-25 | 2001-01-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| KR20000057444A (ko) * | 1996-12-09 | 2000-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 심기능부전 및 심실확장의 치료 및 예방 방법 |
| SI0946166T1 (en) * | 1996-12-17 | 2004-06-30 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for promoting wound healing |
| JP2001507342A (ja) * | 1996-12-17 | 2001-06-05 | ワーナー−ランバート・コンパニー | 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用 |
| US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| ID25921A (id) * | 1997-04-28 | 2000-11-09 | Texas Biotechnology Corp | Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| PT877019E (pt) * | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
| US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| EP1918278A1 (en) | 1998-02-04 | 2008-05-07 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| WO2000015213A1 (en) * | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Remedal or preventive agent for congestive heart failure |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
| BR0007784A (pt) | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto |
| US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
| US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
| US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
| US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| CN1610661A (zh) | 2001-11-01 | 2005-04-27 | 惠氏控股公司 | 用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸 |
| EP1465861B1 (en) * | 2001-12-20 | 2009-05-06 | Bristol-Myers Squibb Company | Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors |
| US6864478B2 (en) * | 2002-04-22 | 2005-03-08 | Visx, Incorporation | Beam position monitoring for laser eye surgery |
| WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
| CA2511521C (en) | 2002-12-30 | 2012-02-07 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7537774B2 (en) * | 2005-12-23 | 2009-05-26 | Orion Therapeautics, Llc | Therapeutic formulation |
| JPWO2007102392A1 (ja) * | 2006-03-03 | 2009-07-23 | 塩野義製薬株式会社 | Ｍｍｐ−１３選択的阻害剤 |
| EP2128134A1 (en) * | 2006-11-02 | 2009-12-02 | Shionogi&Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8084477B2 (en) * | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| EP2278878A4 (en) * | 2008-05-08 | 2014-08-27 | Bristol Myers Squibb Co | 2-ARYL-GYCINAMID DERIVATIVES |
| US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US7977362B2 (en) * | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| US20110071199A1 (en) * | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0100158A3 (en) * | 1982-07-28 | 1985-03-27 | The Upjohn Company | (3-pyridinyl)heteroalkarylalkanols, alkanoic acids and esters |
| DE3330603A1 (de) * | 1983-08-25 | 1985-03-21 | Hoechst Ag, 6230 Frankfurt | Neue 2-amino-alkenylsulfonylharnstoffe |
| GB8609630D0 (en) * | 1986-04-19 | 1986-05-21 | Pfizer Ltd | Anti-arrhythmia agents |
| CA2150550A1 (en) * | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
| CA2110524A1 (en) * | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
| US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| NZ262941A (en) * | 1993-03-29 | 1997-07-27 | Zeneca Ltd | Pyridine derivatives and medicaments |
| IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
| BR9506535A (pt) * | 1994-01-20 | 1997-09-16 | British Biotech Pharm | Inibidores de metaloproteinases |
| US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
| US5817822A (en) * | 1994-06-24 | 1998-10-06 | Novartis Corporation | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids |
| US5919940A (en) * | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| KR20000057444A (ko) * | 1996-12-09 | 2000-09-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 심기능부전 및 심실확장의 치료 및 예방 방법 |
| JP2001507342A (ja) * | 1996-12-17 | 2001-06-05 | ワーナー−ランバート・コンパニー | 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用 |
-
1996
- 1996-10-18 CZ CZ19981467A patent/CZ291659B6/cs not_active IP Right Cessation
- 1996-10-18 ES ES96936718T patent/ES2184893T3/es not_active Expired - Lifetime
- 1996-10-18 HU HU9902083A patent/HUP9902083A3/hu unknown
- 1996-10-18 BR BR9611487A patent/BR9611487A/pt not_active IP Right Cessation
- 1996-10-18 DE DE69624262T patent/DE69624262T2/de not_active Expired - Fee Related
- 1996-10-18 US US09/068,726 patent/US5977141A/en not_active Expired - Fee Related
- 1996-10-18 EP EP96936718A patent/EP0874836B1/en not_active Expired - Lifetime
- 1996-10-18 AT AT96936718T patent/ATE225779T1/de not_active IP Right Cessation
- 1996-10-18 SK SK641-98A patent/SK282833B6/sk unknown
- 1996-10-18 PT PT96936718T patent/PT874836E/pt unknown
- 1996-10-18 PL PL96326700A patent/PL326700A1/xx unknown
- 1996-10-18 AU AU74641/96A patent/AU727569B2/en not_active Ceased
- 1996-10-18 IL IL12390196A patent/IL123901A/xx not_active IP Right Cessation
- 1996-10-18 JP JP09519715A patent/JP2000514779A/ja not_active Abandoned
- 1996-10-18 NZ NZ321293A patent/NZ321293A/en unknown
- 1996-10-18 WO PCT/US1996/016761 patent/WO1997019068A1/en not_active Ceased
- 1996-10-18 DK DK96936718T patent/DK0874836T3/da active
- 1996-11-14 ZA ZA969584A patent/ZA969584B/xx unknown
-
1998
- 1998-05-13 BG BG102448A patent/BG63967B1/bg unknown
- 1998-05-15 NO NO19982223A patent/NO310231B1/no not_active IP Right Cessation
-
1999
- 1999-10-05 US US09/412,707 patent/US6153612A/en not_active Expired - Fee Related
-
2000
- 2000-06-22 US US09/599,306 patent/US6297247B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT874836E (pt) | 2003-02-28 |
| BG63967B1 (bg) | 2003-08-29 |
| ATE225779T1 (de) | 2002-10-15 |
| EP0874836A1 (en) | 1998-11-04 |
| JP2000514779A (ja) | 2000-11-07 |
| CZ291659B6 (cs) | 2003-04-16 |
| US5977141A (en) | 1999-11-02 |
| BR9611487A (pt) | 1999-01-19 |
| NO982223L (no) | 1998-05-15 |
| SK64198A3 (en) | 1998-10-07 |
| NO982223D0 (no) | 1998-05-15 |
| WO1997019068A1 (en) | 1997-05-29 |
| US6153612A (en) | 2000-11-28 |
| AU7464196A (en) | 1997-06-11 |
| BG102448A (en) | 1999-08-31 |
| HUP9902083A3 (en) | 2000-06-28 |
| NZ321293A (en) | 2001-04-27 |
| US6297247B1 (en) | 2001-10-02 |
| HUP9902083A2 (hu) | 1999-10-28 |
| DE69624262D1 (de) | 2002-11-14 |
| IL123901A (en) | 2003-06-24 |
| EP0874836B1 (en) | 2002-10-09 |
| ES2184893T3 (es) | 2003-04-16 |
| NO310231B1 (no) | 2001-06-11 |
| DE69624262T2 (de) | 2003-09-11 |
| SK282833B6 (sk) | 2002-12-03 |
| AU727569B2 (en) | 2000-12-14 |
| PL326700A1 (en) | 1998-10-26 |
| IL123901A0 (en) | 1998-10-30 |
| CZ146798A3 (cs) | 1998-08-12 |
| DK0874836T3 (da) | 2003-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL123901A0 (en) | Sulfonamide inhibitors of matrix metalloproteinases | |
| NZ509439A (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | |
| BR9612188A (pt) | Cetoácidos aromáticos e seus derivados como inibidores de metaloproteinases de matriz | |
| DE69419473D1 (de) | Peptidylderivate als inhibitoren von metalloproteinase | |
| BR9712794A (pt) | Compostos para e um método de inibição de metaloproteinases matriciais | |
| DE69131044D1 (de) | Interleukin-i antagonist und seine verwendung | |
| ZA964508B (en) | Tricyclic inhibitors of matrix metalloproteinases | |
| BR0013390A (pt) | Compostos de ácido hidroxâmico úteis como inibidores de metaloproteinase de matriz | |
| ATE167690T1 (de) | Polyetheramidoamine hydrogele als heparinersatz | |
| CA2233560A1 (en) | Sulfonamide inhibitors of matrix metalloproteinases | |
| FR2695562B1 (fr) | Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique. | |
| ATE222762T1 (de) | 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus | |
| ID20165A (id) | Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis | |
| ES2107400T1 (es) | Nueva utilizacion terapeutica de superoxidos dismutasas. | |
| FR2675383B1 (fr) | Utilisation d'un medicament pour la fabrication d'un medicament destine au traitement des vessies hyperactives ou instables. | |
| UY24693A1 (es) | Ácidos bifenil butíricos y sus derivados como inhibidores de metaloproteinasas de matriz | |
| SE9802075D0 (sv) | New use | |
| RU94014672A (ru) | Средство для лечебных аппликаций |